FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Nov. 11, 2005--Andrx Corporation (Nasdaq: ADRX) (“Andrx” or “Company”) announced today that the U.S. District Court for the District of Northern Illinois granted Abbott Laboratories’ motion for a preliminary injunction related to Andrx’s generic Clarithromycin Extended Release Tablets pending a trial on the merits. The Company is evaluating the court’s decision and will determine its course of action.
